Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 10 000 UNITS IN SODIUM CHLORIDE 0 9 versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 10 000 UNITS IN SODIUM CHLORIDE 0 9 versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9% vs MAGNESIUM SULFATE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III (ATIII), inducing a conformational change that accelerates ATIII-mediated inactivation of coagulation factors IIa (thrombin), Xa, IXa, XIa, and XIIa, thereby inhibiting thrombus formation and propagation.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Intravenous: Initial bolus 80 units/kg, then continuous infusion 18 units/kg/hour; subcutaneous: 5000 units every 8-12 hours.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
None Documented
None Documented
30-150 minutes (dose-dependent, nonlinear); at therapeutic doses ~60-90 minutes; prolonged in hepatic/renal impairment.
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Primarily renal (40-60% as unchanged drug); minor biliary/fecal (<10%).
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Category A/B
Category C
Electrolyte
Electrolyte